The New York Times @nytimes
A second dose of Johnson & Johnson’s vaccine substantially increased its protection against the coronavirus, the company said. In a clinical trial, two shots delivered 94% efficacy against mild to severe Covid-19, up from 74% for a single dose. https://t.co/kwrt44Y39D — PolitiTweet.org